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Gamma-hydroxybutyric acid (GHB) and its liquid precursor gamma-butyrolactone (GBL) have become increasingly popular
beyond the clubbing culture resulting in daily consumption and dependence in the broader population. This case report illustrates
the challenges of managing GHB-withdrawal and a possibly superior future approach of its management by titration and tapering
of the addictive agent.
1. Case Report
Mrs. M. is a 36-year-old Caucasian female with severe GBL-
dependence, chronic kidney disease stage V on hemodialysis,
and past alcohol, cocaine, amphetamine, and cannabis abuse.
The patient is very well known from numerous medical and
psychiatric hospitalizations. Once again, Mrs. M. presented
to the emergency room of the University Hospital Zurich in
GHB-withdrawal with subsequent delirium.
As she missed her hemodialysis when intoxicated, the
patient was urgently hemodialyzed with no improvement in
mental status. At that point, her mental status was severely
impaired. She was lying on a stretcher, restless and unable
to cooperate, grasping for two small brown glass bottles
in her bag. Her consciousness was clouded, attention, con-
centration, and memory were severely impaired, and she
was not able to produce a single meaningful sentence. Her
thought process was incoherent as well as impoverished
and no evidence for hallucinations or delusions existed. Her
psychomotor behavior was restless and lacked goal direction,
her affect was flat, impulsivity was nonexistent, and judgment
and insight were severely impaired.
Laboratory studies revealed a mild known anemia; the
hemoglobin was 114 g/L and hematocrit was 31.4% and mean
corpuscular hemoglobin (MCH) as well as mean corpus-
cular hemoglobin concentration (MCHC) was increased.
Electrolytes, liver function tests, and the remaining labora-
tory results were within normal limits. The EKG revealed
a previously documented unspecific S-T elevation, and the
urine toxicology tested only positive for GHB.
Mrs. M. was very well known to the hospital from
previous admissions inGBL-withdrawal and associated delir-
ium. She was managed and detoxified several times with
oral and intravenous benzodiazepines. In those instances,
the management course was challenging and complicated,
with severe behavioral disturbances requiring intensive per-
sonal assistance in order to avert adverse outcomes. The
withdrawal syndrome and delirium responded insufficiently
due to the differences in pharmacodynamics between GHB
and benzodiazepines. Even more, with oral and intravenous
detoxification the hospitalization lasted on averagemore than
a week resulting in significant health care costs.
As the patient obviously attempted to reach for her GBL-
bottles, she was assisted in self-administration of GBL. The
patient was aided in administration of 2–4mL every 5 min-
utes, totaling approximately 20mL over the next half hour.
In this process her mental status cleared, the disturbance of
consciousness remitted, orientation and cognition recovered,
thought process and psychomotor behavior normalized,
and decisional capacity was restored. Then she admitted to
consumption of 40mL GBL prior to hemodialysis. Despite
recommendations to consider further detoxification and
rehabilitation, the patient decided to leave the hospital against
medical advice and since then has not presented again over
the next weeks.
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Among the admissions for GHB-withdrawal, the self-
administration and titration of GBL presented the most
efficient and cost effective approach.
2. Literature Review of GHB-Pharmacology,
GHB-Dependence, GHB-Withdrawal, and
GHB-Management
Initially GHB has been developed as an anesthetic and
developed into a popular psychoactive drug in the clubbing
scene [1]. Summarized from extensive reviews [2–4], GBL,
a precursor of GHB, is primarily used as a solvent in the
pharmaceutical industry and converted to GHB following
hydrolysis by 1–4 lactonase. The plasma half-life of GBL is
short, usually less than one minute. The time to peak serum
levels ranges from 36 to 57 minutes, the elimination half-life
between 30 and 52 minutes.
At least two distinct binding sites have been identified,
the GHB-receptor and GABAB-receptor. The agonistic effect
at the GHB-receptor is excitatory and the weak antagonistic
effect at the GABAB-receptor is inhibitory. Activation of
both receptors—GHB and GABAB—causes the addictive
properties. The activation of the GHB-receptor causes the
release of glutamate. The release of dopamine is biphasic:
low doses stimulate dopamine release via the GHB-receptor,
whereas higher concentrations then inhibit dopamine release
via the GABAB-receptor and, eventually, after an initial phase
of inhibition, dopamine release is again increased via the
GHB-receptor.
More recently, in addition to the action at the low-affinity
metabotropic GABAB-receptor, a high affinity binding site at
the inotropic 𝛼𝛽𝛿-GABAA-receptor site has been identified.
However, the precise role of this high-affinity binding site still
remains elusive [5, 6].
Addiction occurs when prolonged and repeated GHB
use disrupts the balance of brain transmitters and circuits
controlling reward, memory, and cognition leading to com-
pulsive use.The duration of clinical effects is dose-dependent
and ranges from 2.5 to 4 hours. The early GHB-withdrawal
syndrome resembles the alcohol withdrawal syndromewhich
is associated with autonomic instability, tremor, restlessness,
anxiety, and sleeping disorders. GHB-withdrawal usually
lasts 3 to 21 days. Severe withdrawal syndromes can also pro-
duce acute delirium requiring hospitalization, often leading
to intensive care management and possible fatal outcome.
Important differential diagnoses for GHB-withdrawal syn-
drome include alcohol or benzodiazepine withdrawal, delir-
ium caused by somatic conditions, neuroleptic malignant
syndrome, and serotonin syndrome [3, 4]. The mainstay of
management of the GHB-withdrawal syndrome remains the
administration of benzodiazepines. Generally high doses are
required. In contrast to GHB acting on the GABAB-receptor,
benzodiazepines are indirect GABAA-agonists explaining
the requirement for high doses of benzodiazepines [7]. To
date, one study exists managing GHB-withdrawal with the
administration, titration, and tapering of GHB itself [8].
3. Discussion
The case of Mrs. M. illustrates the challenges of managing
GHB-withdrawal and potentially life-threatening complica-
tions such as rhabdomyolysis, seizures, bradycardia, and
cardiac arrest. Due to the different pharmacodynamic mech-
anisms involving the GABAB-receptor in the case of GHB
and theGABAA-receptor in the case of benzodiazepines, very
high doses of benzodiazepine administered over several days
may be required without fully achieving symptom control,
causing distress for patient and staff as well as a potentially
fatal outcome. The exact contribution of activity of the
high-affinity 𝛼𝛽𝛿-GABAA-receptor site of GHB still remains
elusive in the withdrawal process.
The administration of related compounds such as the
use of benzodiazepine in alcohol withdrawal indicates that
the administration of GHB could be a superior management
approach reducing distress, length of hospitalization, and
health care costs. Even further, similar to methadone main-
tenance, the controlled administration of GHB could be a
future perspective for these patients.
In summary, in this case, self-administration of GBL
represented the superior management approach for GHB-
dependence, GHB-withdrawal, and delirium exceeding the
effectiveness of benzodiazepine administered orally or intra-
venously. Although the administration of GBL—which is
illegal inmost legislatures—cannot be a routine approach, the
administration of GHB, the metabolite of GBL, represents a
viable option.The administration of GHB could be the future
approach for the management of GHB-dependence, GHB-
withdrawal, andGHB-induced delirium.The implications on
length of stay and health care cost have not yet been assessed
and merited further investigation.
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